132 related articles for article (PubMed ID: 32668858)
1. [A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection].
Yabe S; Iwamoto N; Inokuchi T; Nara M; Saita C; Onishi M; Goto R; Yonekura R; Ishiba T; Honda Y; Miyamoto H; Aruga T
Gan To Kagaku Ryoho; 2020 Jul; 47(7):1089-1092. PubMed ID: 32668858
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Recurrent Breast Cancer with Improving Activities of Daily Living by Olaparib Treatment].
Nakagawa T; Oda G; Okamoto K; Ishikawa T; Wakana K; Oshima N
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1556-1558. PubMed ID: 35046254
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Metastatic Recurrent Breast Cancer Successfully with Olaparib in Late Line Therapy].
Soyama M; Kunihisa T; Shimada N; Suzuki H; Ookawa Y; Okamoto A; Yamamoto M; Miki M; Mizumoto S; Baba M; Tanino H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1153-1155. PubMed ID: 34521794
[TBL] [Abstract][Full Text] [Related]
4. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
5. [Axillary Arterial Bleeding with Administration of Bevacizumab plus Paclitaxel in a Patient with Recurrent Breast Cancer-A Case Report].
Tsuruda Y; Masuda T; Hayashi N; Noda M; Otsu H; Kuroda Y; Eguchi H; Tanaka F; Natsugoe S; Mimori K
Gan To Kagaku Ryoho; 2020 Jan; 47(1):117-119. PubMed ID: 32381877
[TBL] [Abstract][Full Text] [Related]
6. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
7. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
8. [Case of Recurrent Breast Cancer with BRCA2 Mutation Successfully Treated with Olaparib Therapy].
Yoneda H; Shimizu Y; Masuda R
Gan To Kagaku Ryoho; 2020 May; 47(5):815-818. PubMed ID: 32408326
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
10. Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report.
Caputo R; Pagliuca M; Pensabene M; Parola S; De Laurentiis M
Front Oncol; 2023; 13():1214660. PubMed ID: 37601649
[TBL] [Abstract][Full Text] [Related]
11. [A Case of Recurrent Breast Cancer That Was BRCA1 Pathogenic Variant-Positive Successfully Treated with PARP Inhibitor].
Aoyagi T; Namura M; Sakata H; Tamanuki T; Iwai M; Iwata K; Takahashi H; Matsuzaki H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1462-1464. PubMed ID: 38303308
[TBL] [Abstract][Full Text] [Related]
12. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
13. [Interstitial Pneumonia Caused by Olaparib during Treatment of Breast Cancer-A Case Report].
Suzuki H; Oshino T; Hagio K; Takeshita T; Yamashita H
Gan To Kagaku Ryoho; 2020 Sep; 47(9):1351-1353. PubMed ID: 33130698
[TBL] [Abstract][Full Text] [Related]
14. [The Treatment of Olaparib for BRCA Positive-Metastatic Breast Cancer Patient].
Yamamoto D; Yamamoto C; Okugawa H; Tsubota Y; Kawakami K
Gan To Kagaku Ryoho; 2021 Mar; 48(3):455-456. PubMed ID: 33790186
[TBL] [Abstract][Full Text] [Related]
15. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
16. [A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1].
Nomura T; Sonoo H; Miyake A; Souda M; Yamamoto Y; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Kurebayashi J
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1607-10. PubMed ID: 18799922
[TBL] [Abstract][Full Text] [Related]
17. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
18. [Bevacizumab plus Paclitaxel Therapy Was Effective for Metastatic Breast Cancer with Dysphagia Due to Mediastinal Lymph Node Metastasis-A Case Report].
Kodera A; Inoue H; Ogura K; Sakaguchi S; Yukawa H; Matsuoka A; Tanaka N; Kinoshita J; Yoshimatsu K; Naritaka Y; Hirano A
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2276-2278. PubMed ID: 30692436
[TBL] [Abstract][Full Text] [Related]
19. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
20. [A complete response following treatment with Paclitaxel and bevacizumab for metastatic breast cancer].
Tsubota Y; Sueoka N; Yamamoto D
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1954-6. PubMed ID: 25731387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
